Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

BMJ Case Rep. 2021 Apr 22;14(4):e242956. doi: 10.1136/bcr-2021-242956.

Abstract

Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1, presented to hospital with a rapidly progressive ascending muscle weakness and back pain in the absence of any other triggers. He also had a negative COVID-19 swab during admission. A diagnosis of Guillain-Barre syndrome was confirmed by correlating the clinical features with cerebrospinal fluid analysis, nerve conduction studies and MRI of the brain and whole spine. The patient received treatment with 5 days of intravenous immunoglobulin and did not require any respiratory support. He was also regularly reviewed by a multidisciplinary team consisting of neurologists, speech and language therapists, and physiotherapists and is on the course to a recovery.

Keywords: COVID-19; healthcare improvement and patient safety; neurology; radiology; vaccination/immunisation.

Publication types

  • Case Reports

MeSH terms

  • Adenoviruses, Simian
  • Adult
  • Animals
  • COVID-19 Vaccines / adverse effects*
  • COVID-19*
  • ChAdOx1 nCoV-19
  • Guillain-Barre Syndrome / chemically induced*
  • Humans
  • Male
  • Pan troglodytes

Substances

  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19